

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CD20 antibody [EP459Y] - Carboxyterminal end

RRID:AB_1640323

Type: Antibody

Proper Citation

Abcam Cat# ab78237, RRID:AB_1640323

Antibody Information

URL: http://antibodyregistry.org/AB_1640323

Proper Citation: Abcam Cat# ab78237, RRID:AB_1640323

Target Antigen: CD20 antibody [EP459Y] - Carboxyterminal end

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cytometry; Western Blot; Immunohistochemistry - fixed; Immunohistochemistry; Immunoprecipitation; Flow Cyt, IHC-P, IP, WB

Antibody Name: CD20 antibody [EP459Y] - Carboxyterminal end

Description: This monoclonal targets CD20 antibody [EP459Y] - Carboxyterminal end

Target Organism: monkey, human

Antibody ID: AB_1640323

Vendor: Abcam

Catalog Number: ab78237

Record Creation Time: 20250820T032213+0000

Record Last Update: 20250820T160417+0000

Ratings and Alerts

No rating or validation information has been found for CD20 antibody [EP459Y] - Carboxyterminal end.

No alerts have been found for CD20 antibody [EP459Y] - Carboxyterminal end.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang Z, et al. (2025) Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. *Cancer cell*, 43(6), 1025.

Peng T, et al. (2025) Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. *Cell stem cell*, 32(4), 652.

Li X, et al. (2025) Integrated spatial transcriptomic profiling to dissect the cellular characteristics of tumor-associated tertiary lymphoid structures. *Cell reports*, 44(9), 116250.

Zhang YP, et al. (2025) PAI-1-driven SFRP2^{high} cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. *Cancer cell*, 43(5), 856.

Xia TL, et al. (2025) TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial. *Med (New York, N.Y.)*, 6(11), 100846.

Xing X, et al. (2025) Pan-cancer human brain metastases atlas at single-cell resolution. *Cancer cell*, 43(7), 1242.

Quandt Z, et al. (2025) Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. *Journal for immunotherapy of cancer*, 13(8).

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. *Cell reports. Medicine*, 6(9), 102298.

Zhang Y, et al. (2025) Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. *Cancer cell*, 43(3), 446.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Chen S, et al. (2024) Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance. *NPJ precision oncology*, 8(1), 159.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.

Chen Y, et al. (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. *Cancer cell*, 42(7), 1268.

Hong J, et al. (2023) Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection. *Cell reports. Medicine*, 4(11), 101296.

Liu Z, et al. (2023) Progenitor-like exhausted SPY1+CD8+T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. *Cancer cell*, 41(11), 1852.

Liu Z, et al. (2023) Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. *Cancer cell*, 41(1), 181.

Ye X, et al. (2022) A single-cell atlas of diffuse large B cell lymphoma. *Cell reports*, 39(3), 110713.

Mourcin F, et al. (2021) Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. *Immunity*, 54(8), 1788.

Fu J, et al. (2019) Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are Maintained by a Circulating Pool. *Cell stem cell*, 24(2), 227.